7 Primus Biosciences, Inc.
- Biotech or pharma, therapeutic R&D
We are a biotechnology company focused on oncology, dedicated to developing innovative targeted therapeutics to eradicate cancer. We have created a first-in-class small molecule BAK activator that selectively induces cancer cell death, leading to significant tumor suppression in vivo while sparing normal tissues. Additionally, we developed the pioneering comBYSelect platform technology to produce bispecific antibodies that target various tumor-associated antigens with high specificity, functionality, and sustainability, as well as Fc fusion proteins like cytokine traps. Furthermore, by utilizing a range of bispecific antibodies along with both novel and established payload systems, we aim to create innovative bispecific antibody-drug conjugates for precise cancer treatments that benefit patients.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}